ICMR and Panacea Biotec conduct third phase trials for indigenous dengue vaccine in India with promising results.

In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...

Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting ...

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 ...

UNM health scientists are seeking funding from the Alzheimer's Association and other venture capitalists to launch phase 1 of ...

LUND, SWEDEN / ACCESS Newswire / July 14, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that it has dosed the first patient ...

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...